A comparative binding mechanism between human serum albumin and α-1-acid glycoprotein with corilagin

Biophysical and computational approach

Daniel Pushparaju Yeggoni, Aparna Rachamallu, S. Rajagopal

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The binding of corilagin with plasma serum proteins like human serum albumin (HSA) and α-1-acid glycoprotein (AGP) was investigated under physiological conditions. To understand the pharmacological importance of the corilagin molecule, anti-inflammatory activity on mouse macrophages (RAW 264.7) cell lines was studied. This study reveals that corilagin caused an increase in inhibition growth of inflamed macrophages in concentration-dependent manner with an IC50 value of 66 μM. Further, intrinsic fluorescence of HSA and AGP was quenched upon titration of corilagin, and the binding constants obtained from fluorescence emission was found to be Kcorilagin 4.2 ± 0.02 × 105 M-1 which corresponds to the free energy of -7.6 kcal M-1 at 25°C for a HSA-corilagin complex. Interestingly, corilagin showed binding with AGP, an acute phase protein, and the binding constant was found to be Kcorilagin = 1.5 ± 0.01 × 104 M-1 and its free energy was -5.6 kcal M-1 at 25°C. Further, the average binding distance, r, between the donor (HSA) and acceptor (corilagin) was calculated and found to be 1.32 nm according to Förster's theory of non-radiation energy transfer. Later, circular dichroism studies emphasized that there are marginal changes in secondary structural conformation of HSA in the presence of corilagin. Corilagin is specifically bound to site I of HSA which was proved by site specific marker, phenylbutazone. Furthermore, the binding details between corilagin and HSA revealed that corilagin was bound to subdomain IIA through multiple interactions like hydrogen bonding and hydrophobic effects. Molecular dynamic studies (MD) also suggest that binding is very precise to site I (IIA domain) on HSA. Also, MD studies showed that HSA-corilagin complex reaches equilibration state at around 4 ns, which proves that the HSA-corilagin complex is stable in nature, hence the experimental and computational results are in agreement. Thus, examining the interaction mechanism of corilagin with plasma proteins may play a critical role in developing corilagin inspired drugs.

Original languageEnglish
Pages (from-to)40225-40237
Number of pages13
JournalRSC Advances
Volume6
Issue number46
DOIs
Publication statusPublished - 2016

Fingerprint

Glycoproteins
Serum Albumin
Macrophages
Proteins
Free energy
Acids
Molecular dynamics
Fluorescence
Plasmas
Dichroism
Beam plasma interactions
Titration
Energy transfer
Conformations
Hydrogen bonds
Cells
Molecules
corilagin
Blood Proteins
Phenylbutazone

ASJC Scopus subject areas

  • Chemical Engineering(all)
  • Chemistry(all)

Cite this

A comparative binding mechanism between human serum albumin and α-1-acid glycoprotein with corilagin : Biophysical and computational approach. / Yeggoni, Daniel Pushparaju; Rachamallu, Aparna; Rajagopal, S.

In: RSC Advances, Vol. 6, No. 46, 2016, p. 40225-40237.

Research output: Contribution to journalArticle

@article{f2419d50088f4bf0a24ddeb60d94cc22,
title = "A comparative binding mechanism between human serum albumin and α-1-acid glycoprotein with corilagin: Biophysical and computational approach",
abstract = "The binding of corilagin with plasma serum proteins like human serum albumin (HSA) and α-1-acid glycoprotein (AGP) was investigated under physiological conditions. To understand the pharmacological importance of the corilagin molecule, anti-inflammatory activity on mouse macrophages (RAW 264.7) cell lines was studied. This study reveals that corilagin caused an increase in inhibition growth of inflamed macrophages in concentration-dependent manner with an IC50 value of 66 μM. Further, intrinsic fluorescence of HSA and AGP was quenched upon titration of corilagin, and the binding constants obtained from fluorescence emission was found to be Kcorilagin 4.2 ± 0.02 × 105 M-1 which corresponds to the free energy of -7.6 kcal M-1 at 25°C for a HSA-corilagin complex. Interestingly, corilagin showed binding with AGP, an acute phase protein, and the binding constant was found to be Kcorilagin = 1.5 ± 0.01 × 104 M-1 and its free energy was -5.6 kcal M-1 at 25°C. Further, the average binding distance, r, between the donor (HSA) and acceptor (corilagin) was calculated and found to be 1.32 nm according to F{\"o}rster's theory of non-radiation energy transfer. Later, circular dichroism studies emphasized that there are marginal changes in secondary structural conformation of HSA in the presence of corilagin. Corilagin is specifically bound to site I of HSA which was proved by site specific marker, phenylbutazone. Furthermore, the binding details between corilagin and HSA revealed that corilagin was bound to subdomain IIA through multiple interactions like hydrogen bonding and hydrophobic effects. Molecular dynamic studies (MD) also suggest that binding is very precise to site I (IIA domain) on HSA. Also, MD studies showed that HSA-corilagin complex reaches equilibration state at around 4 ns, which proves that the HSA-corilagin complex is stable in nature, hence the experimental and computational results are in agreement. Thus, examining the interaction mechanism of corilagin with plasma proteins may play a critical role in developing corilagin inspired drugs.",
author = "Yeggoni, {Daniel Pushparaju} and Aparna Rachamallu and S. Rajagopal",
year = "2016",
doi = "10.1039/c6ra06837e",
language = "English",
volume = "6",
pages = "40225--40237",
journal = "RSC Advances",
issn = "2046-2069",
publisher = "Royal Society of Chemistry",
number = "46",

}

TY - JOUR

T1 - A comparative binding mechanism between human serum albumin and α-1-acid glycoprotein with corilagin

T2 - Biophysical and computational approach

AU - Yeggoni, Daniel Pushparaju

AU - Rachamallu, Aparna

AU - Rajagopal, S.

PY - 2016

Y1 - 2016

N2 - The binding of corilagin with plasma serum proteins like human serum albumin (HSA) and α-1-acid glycoprotein (AGP) was investigated under physiological conditions. To understand the pharmacological importance of the corilagin molecule, anti-inflammatory activity on mouse macrophages (RAW 264.7) cell lines was studied. This study reveals that corilagin caused an increase in inhibition growth of inflamed macrophages in concentration-dependent manner with an IC50 value of 66 μM. Further, intrinsic fluorescence of HSA and AGP was quenched upon titration of corilagin, and the binding constants obtained from fluorescence emission was found to be Kcorilagin 4.2 ± 0.02 × 105 M-1 which corresponds to the free energy of -7.6 kcal M-1 at 25°C for a HSA-corilagin complex. Interestingly, corilagin showed binding with AGP, an acute phase protein, and the binding constant was found to be Kcorilagin = 1.5 ± 0.01 × 104 M-1 and its free energy was -5.6 kcal M-1 at 25°C. Further, the average binding distance, r, between the donor (HSA) and acceptor (corilagin) was calculated and found to be 1.32 nm according to Förster's theory of non-radiation energy transfer. Later, circular dichroism studies emphasized that there are marginal changes in secondary structural conformation of HSA in the presence of corilagin. Corilagin is specifically bound to site I of HSA which was proved by site specific marker, phenylbutazone. Furthermore, the binding details between corilagin and HSA revealed that corilagin was bound to subdomain IIA through multiple interactions like hydrogen bonding and hydrophobic effects. Molecular dynamic studies (MD) also suggest that binding is very precise to site I (IIA domain) on HSA. Also, MD studies showed that HSA-corilagin complex reaches equilibration state at around 4 ns, which proves that the HSA-corilagin complex is stable in nature, hence the experimental and computational results are in agreement. Thus, examining the interaction mechanism of corilagin with plasma proteins may play a critical role in developing corilagin inspired drugs.

AB - The binding of corilagin with plasma serum proteins like human serum albumin (HSA) and α-1-acid glycoprotein (AGP) was investigated under physiological conditions. To understand the pharmacological importance of the corilagin molecule, anti-inflammatory activity on mouse macrophages (RAW 264.7) cell lines was studied. This study reveals that corilagin caused an increase in inhibition growth of inflamed macrophages in concentration-dependent manner with an IC50 value of 66 μM. Further, intrinsic fluorescence of HSA and AGP was quenched upon titration of corilagin, and the binding constants obtained from fluorescence emission was found to be Kcorilagin 4.2 ± 0.02 × 105 M-1 which corresponds to the free energy of -7.6 kcal M-1 at 25°C for a HSA-corilagin complex. Interestingly, corilagin showed binding with AGP, an acute phase protein, and the binding constant was found to be Kcorilagin = 1.5 ± 0.01 × 104 M-1 and its free energy was -5.6 kcal M-1 at 25°C. Further, the average binding distance, r, between the donor (HSA) and acceptor (corilagin) was calculated and found to be 1.32 nm according to Förster's theory of non-radiation energy transfer. Later, circular dichroism studies emphasized that there are marginal changes in secondary structural conformation of HSA in the presence of corilagin. Corilagin is specifically bound to site I of HSA which was proved by site specific marker, phenylbutazone. Furthermore, the binding details between corilagin and HSA revealed that corilagin was bound to subdomain IIA through multiple interactions like hydrogen bonding and hydrophobic effects. Molecular dynamic studies (MD) also suggest that binding is very precise to site I (IIA domain) on HSA. Also, MD studies showed that HSA-corilagin complex reaches equilibration state at around 4 ns, which proves that the HSA-corilagin complex is stable in nature, hence the experimental and computational results are in agreement. Thus, examining the interaction mechanism of corilagin with plasma proteins may play a critical role in developing corilagin inspired drugs.

UR - http://www.scopus.com/inward/record.url?scp=84971003244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971003244&partnerID=8YFLogxK

U2 - 10.1039/c6ra06837e

DO - 10.1039/c6ra06837e

M3 - Article

VL - 6

SP - 40225

EP - 40237

JO - RSC Advances

JF - RSC Advances

SN - 2046-2069

IS - 46

ER -